HUE039368T2 - Kristályos pirimidin származékok szuszpenziói kapszulákban - Google Patents

Kristályos pirimidin származékok szuszpenziói kapszulákban

Info

Publication number
HUE039368T2
HUE039368T2 HUE06831479A HUE06831479A HUE039368T2 HU E039368 T2 HUE039368 T2 HU E039368T2 HU E06831479 A HUE06831479 A HU E06831479A HU E06831479 A HUE06831479 A HU E06831479A HU E039368 T2 HUE039368 T2 HU E039368T2
Authority
HU
Hungary
Prior art keywords
capsules
suspensions
pyrimidine nucleoside
nucleoside derivatives
crystalline pyrimidine
Prior art date
Application number
HUE06831479A
Other languages
English (en)
Inventor
Robert Westwood
Alistair Selkirk
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of HUE039368T2 publication Critical patent/HUE039368T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE06831479A 2005-12-23 2006-12-22 Kristályos pirimidin származékok szuszpenziói kapszulákban HUE039368T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0526419.7A GB0526419D0 (en) 2005-12-23 2005-12-23 Formulation

Publications (1)

Publication Number Publication Date
HUE039368T2 true HUE039368T2 (hu) 2018-12-28

Family

ID=35841215

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06831479A HUE039368T2 (hu) 2005-12-23 2006-12-22 Kristályos pirimidin származékok szuszpenziói kapszulákban

Country Status (17)

Country Link
US (1) US8497291B2 (hu)
EP (1) EP1962814B1 (hu)
JP (2) JP5443763B2 (hu)
CN (1) CN101346132B (hu)
AU (1) AU2006327951B2 (hu)
BR (1) BRPI0620229B8 (hu)
CA (1) CA2633308C (hu)
DK (1) DK1962814T3 (hu)
ES (1) ES2672106T3 (hu)
GB (1) GB0526419D0 (hu)
HK (1) HK1126412A1 (hu)
HU (1) HUE039368T2 (hu)
IL (1) IL192348A (hu)
PT (1) PT1962814T (hu)
RU (1) RU2428972C2 (hu)
TR (1) TR201808182T4 (hu)
WO (1) WO2007072061A2 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302007C (zh) 2001-04-30 2007-02-28 葛兰素集团有限公司 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.-硫代羧酸酯衍生物
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
EP2148676B1 (en) * 2007-04-25 2016-05-25 Cyclacel Limited Use of sapacitabine to treat proliferative disease
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
CN102088969B (zh) 2008-06-09 2013-06-12 西克拉塞尔有限公司 沙帕他滨或cndac与dna甲基转移酶抑制剂如地西他滨和普鲁卡因的组合
RU2538593C2 (ru) * 2009-05-15 2015-01-10 Дельта-Флай Фарма, Инк. НОВЫЕ СТАБИЛЬНЫЕ КРИСТАЛЛЫ МОНОГИДРОХЛОРИДА 1-(2-β-D-АРАБИНОФУРАНОЗИЛ)ЦИТОЗИНА
JP6209446B2 (ja) 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
EP2696878B1 (en) 2011-04-14 2019-07-10 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法
JP6286421B2 (ja) 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン
EP2961384B1 (en) * 2013-02-28 2019-08-28 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CN106963742B (zh) * 2016-11-07 2021-02-23 澳门大学 中药固液胶囊及其制备方法
WO2019081951A1 (en) 2017-10-27 2019-05-02 Cyclacel Limited DOSAGE REGIME
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126573T3 (es) * 1991-04-22 1999-04-01 Otsuka Pharma Co Ltd Derivado de pirazol (1,5-a)pirimidina y agente antiinflamatorio que contiene este derivado.
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
KR19980073479A (ko) * 1997-03-14 1998-11-05 한스루돌프하우스, 니콜케르커 사이클로스포린-함유 연질캅셀제
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
JP3748536B2 (ja) * 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
DE60222803T2 (de) * 2001-12-21 2008-07-17 Supernus Pharmaceuticals, Inc. Orale kapselformulierung mit verbesserter physikalischer stabilität
JP5096658B2 (ja) * 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
US20050249802A1 (en) * 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use

Also Published As

Publication number Publication date
CA2633308A1 (en) 2007-06-28
IL192348A0 (en) 2009-08-03
DK1962814T3 (en) 2018-08-06
PT1962814T (pt) 2018-06-22
US20090074856A1 (en) 2009-03-19
WO2007072061A2 (en) 2007-06-28
GB0526419D0 (en) 2006-02-08
WO2007072061A3 (en) 2007-10-25
BRPI0620229B1 (pt) 2020-09-15
AU2006327951A1 (en) 2007-06-28
BRPI0620229B8 (pt) 2021-05-25
EP1962814A2 (en) 2008-09-03
JP5443763B2 (ja) 2014-03-19
CN101346132A (zh) 2009-01-14
JP2013189463A (ja) 2013-09-26
AU2006327951B2 (en) 2012-09-06
ES2672106T3 (es) 2018-06-12
JP2009520797A (ja) 2009-05-28
HK1126412A1 (en) 2009-09-04
RU2008130411A (ru) 2010-01-27
IL192348A (en) 2016-02-29
CA2633308C (en) 2014-06-17
CN101346132B (zh) 2013-01-16
EP1962814B1 (en) 2018-04-25
TR201808182T4 (tr) 2018-07-23
RU2428972C2 (ru) 2011-09-20
BRPI0620229A8 (pt) 2018-01-02
US8497291B2 (en) 2013-07-30
BRPI0620229A2 (pt) 2011-11-01

Similar Documents

Publication Publication Date Title
IL192348A0 (en) Crystalline pyrimidine nucleoside derivatives suspensions in capsules
AP2008004486A0 (en) Pyrimidine derivatives
GB0525080D0 (en) Pyrimidine derivatives
HK1203488A1 (en) Pyrimidine substituted purine derivatives
GB0525083D0 (en) Pyrimidine derivatives
IL181433A0 (en) Pyrimidine derivatives
IL192610A0 (en) Pyrimidine derivatives
PL1784399T3 (pl) Pochodne pirymidyny
GB0525081D0 (en) Pyrimidine derivatives
ZA200800353B (en) Pyrazine derivatives useful as adenosine receptor antagonists
GB0614579D0 (en) Pyrimidine derivatives
GB0415364D0 (en) Pyrimidine derivatives
HK1104553A1 (en) Pyrimidine derivatives
ZA200804958B (en) Antiviral nucleosides
HRP20140377T1 (en) Pyrimidine derivatives
EP1724267A4 (en) PYRIMIDINE DERIVATIVE
IL190336A0 (en) Imidazopyridine derivatives as a2b adenosine receptor antagonists
IL186939A0 (en) Pyrimidine derivatives and their use as
IL195018A0 (en) Piperidinyl pyrimidine derivatives
ZA201000107B (en) Pyrimidine derivatives 934
IL184779A0 (en) Novel pyrimidine nucleoside compound or salt thereof
GB0415367D0 (en) Pyrimidine derivatives
PL1951730T3 (pl) Pochodne pirymidyny połączone przez grupy heteroalkilowe
GB0505786D0 (en) A2b adenosine receptor antagonists